NCT07136974View on ClinicalTrials.gov

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2030

Conditions
Breast CancerHER2 + Breast Cancer
Interventions
DRUG

TQB2102

TQB2102 is administered intravenously at 6 mg/kg every 3 weeks for 6 cycles.

DRUG

Docetaxel + Carboplatin + Trastuzumab +Pertuzumab

Docetaxel 75 mg/m2(day 1) , Carboplatin (AUC=6) (day 1), Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Pertuzumab (840mg first dose, 420mg/kg sequential) are administered intravenously every 3 weeks for 6 cycles.

Trial Locations (1)

Unknown

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV